Cargando…
Real‐life benefits of intrajejunal levodopa infusion therapy in four patients with the parkinsonian variant of progressive supranuclear palsy: A 1‐year follow‐up data report
BACKGROUND: Progressive supranuclear palsy (PSP) is a progressive neurodegenerative condition presenting with different clinical endophenotypes. The parkinsonian variant of PSP (PSP‐P) is characterised by early but fading responsiveness to high‐dose levodopa therapy; however, high‐dose oral therapy...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9480946/ https://www.ncbi.nlm.nih.gov/pubmed/35943202 http://dx.doi.org/10.1002/brb3.2547 |
_version_ | 1784791153956093952 |
---|---|
author | Metta, Vinod Chaudhuri, K. Ray Leta, Valentina Mridula, Kandadai Rukmini Koduri, Chaitanya Deepak, Sai Kalpala, Rakesh Reddy, Nageswar Chung‐Faye, Guy Borgohain, Rupam |
author_facet | Metta, Vinod Chaudhuri, K. Ray Leta, Valentina Mridula, Kandadai Rukmini Koduri, Chaitanya Deepak, Sai Kalpala, Rakesh Reddy, Nageswar Chung‐Faye, Guy Borgohain, Rupam |
author_sort | Metta, Vinod |
collection | PubMed |
description | BACKGROUND: Progressive supranuclear palsy (PSP) is a progressive neurodegenerative condition presenting with different clinical endophenotypes. The parkinsonian variant of PSP (PSP‐P) is characterised by early but fading responsiveness to high‐dose levodopa therapy; however, high‐dose oral therapy is often associated with intolerance due to dopaminergic side effects and so doses may have to be capped despite clinical benefits. Evidence from animal models and real‐life registries suggest far higher doses of levodopa can be tolerated if given in a continuous drug delivery (CDD) manner. We investigated tolerance and possible clinical benefits in patients with PSP‐P still responsive to levodopa after initiating CDD in the form of intrajejunal levodopa infusion (IJLI) therapy as part of a compassionate usage program (CU). METHODS: This is an observational clinical data report from the IJLI implementation program undertaken in regional tertiary referral Parkinson's centres in India and at King's College Hospital London, Dubai as part of a CU. Four patients with PSP‐P receiving IJLI as a part of a CU underwent evaluations of liver and renal function, motor and nonmotor function, quality of life, sleep dysfunction, fatigue, anxiety and depression, and cognitive impairment at baseline and 6 and 12 months post‐IJLI initiation. RESULTS: In total, three out of four patients successfully completed 12 months of treatment (6 months in one patient). All four patients showed good tolerability to IJLI even at higher doses (1400 and 1960 mg at 6 and 12 months, respectively) when compared to oral levodopa (812.5 ± 103 levodopa equivalent daily dose [LEDD]) and presented with overall persistent improvements in motor and nonmotor scores and quality‐of‐life scores at 6 and 12 months post‐IJLI. All patients showed improvement in estimated glomerular filtration rate (43.50 ml/min/1.73 m(2) to 67.5 ml/min/1.73 m(2) and 79.5 ml/min/1.73 m(2) at 6 and 12 months, respectively). CONCLUSIONS: IJLI led to persistent beneficial effects on motor and some nonmotor aspects in patients with PSP‐P at up to 12 months after treatment with associated improvement in overall renal function. |
format | Online Article Text |
id | pubmed-9480946 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-94809462022-09-28 Real‐life benefits of intrajejunal levodopa infusion therapy in four patients with the parkinsonian variant of progressive supranuclear palsy: A 1‐year follow‐up data report Metta, Vinod Chaudhuri, K. Ray Leta, Valentina Mridula, Kandadai Rukmini Koduri, Chaitanya Deepak, Sai Kalpala, Rakesh Reddy, Nageswar Chung‐Faye, Guy Borgohain, Rupam Brain Behav Original Articles BACKGROUND: Progressive supranuclear palsy (PSP) is a progressive neurodegenerative condition presenting with different clinical endophenotypes. The parkinsonian variant of PSP (PSP‐P) is characterised by early but fading responsiveness to high‐dose levodopa therapy; however, high‐dose oral therapy is often associated with intolerance due to dopaminergic side effects and so doses may have to be capped despite clinical benefits. Evidence from animal models and real‐life registries suggest far higher doses of levodopa can be tolerated if given in a continuous drug delivery (CDD) manner. We investigated tolerance and possible clinical benefits in patients with PSP‐P still responsive to levodopa after initiating CDD in the form of intrajejunal levodopa infusion (IJLI) therapy as part of a compassionate usage program (CU). METHODS: This is an observational clinical data report from the IJLI implementation program undertaken in regional tertiary referral Parkinson's centres in India and at King's College Hospital London, Dubai as part of a CU. Four patients with PSP‐P receiving IJLI as a part of a CU underwent evaluations of liver and renal function, motor and nonmotor function, quality of life, sleep dysfunction, fatigue, anxiety and depression, and cognitive impairment at baseline and 6 and 12 months post‐IJLI initiation. RESULTS: In total, three out of four patients successfully completed 12 months of treatment (6 months in one patient). All four patients showed good tolerability to IJLI even at higher doses (1400 and 1960 mg at 6 and 12 months, respectively) when compared to oral levodopa (812.5 ± 103 levodopa equivalent daily dose [LEDD]) and presented with overall persistent improvements in motor and nonmotor scores and quality‐of‐life scores at 6 and 12 months post‐IJLI. All patients showed improvement in estimated glomerular filtration rate (43.50 ml/min/1.73 m(2) to 67.5 ml/min/1.73 m(2) and 79.5 ml/min/1.73 m(2) at 6 and 12 months, respectively). CONCLUSIONS: IJLI led to persistent beneficial effects on motor and some nonmotor aspects in patients with PSP‐P at up to 12 months after treatment with associated improvement in overall renal function. John Wiley and Sons Inc. 2022-08-09 /pmc/articles/PMC9480946/ /pubmed/35943202 http://dx.doi.org/10.1002/brb3.2547 Text en © 2022 The Authors. Brain and Behavior published by Wiley Periodicals LLC. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Articles Metta, Vinod Chaudhuri, K. Ray Leta, Valentina Mridula, Kandadai Rukmini Koduri, Chaitanya Deepak, Sai Kalpala, Rakesh Reddy, Nageswar Chung‐Faye, Guy Borgohain, Rupam Real‐life benefits of intrajejunal levodopa infusion therapy in four patients with the parkinsonian variant of progressive supranuclear palsy: A 1‐year follow‐up data report |
title | Real‐life benefits of intrajejunal levodopa infusion therapy in four patients with the parkinsonian variant of progressive supranuclear palsy: A 1‐year follow‐up data report |
title_full | Real‐life benefits of intrajejunal levodopa infusion therapy in four patients with the parkinsonian variant of progressive supranuclear palsy: A 1‐year follow‐up data report |
title_fullStr | Real‐life benefits of intrajejunal levodopa infusion therapy in four patients with the parkinsonian variant of progressive supranuclear palsy: A 1‐year follow‐up data report |
title_full_unstemmed | Real‐life benefits of intrajejunal levodopa infusion therapy in four patients with the parkinsonian variant of progressive supranuclear palsy: A 1‐year follow‐up data report |
title_short | Real‐life benefits of intrajejunal levodopa infusion therapy in four patients with the parkinsonian variant of progressive supranuclear palsy: A 1‐year follow‐up data report |
title_sort | real‐life benefits of intrajejunal levodopa infusion therapy in four patients with the parkinsonian variant of progressive supranuclear palsy: a 1‐year follow‐up data report |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9480946/ https://www.ncbi.nlm.nih.gov/pubmed/35943202 http://dx.doi.org/10.1002/brb3.2547 |
work_keys_str_mv | AT mettavinod reallifebenefitsofintrajejunallevodopainfusiontherapyinfourpatientswiththeparkinsonianvariantofprogressivesupranuclearpalsya1yearfollowupdatareport AT chaudhurikray reallifebenefitsofintrajejunallevodopainfusiontherapyinfourpatientswiththeparkinsonianvariantofprogressivesupranuclearpalsya1yearfollowupdatareport AT letavalentina reallifebenefitsofintrajejunallevodopainfusiontherapyinfourpatientswiththeparkinsonianvariantofprogressivesupranuclearpalsya1yearfollowupdatareport AT mridulakandadairukmini reallifebenefitsofintrajejunallevodopainfusiontherapyinfourpatientswiththeparkinsonianvariantofprogressivesupranuclearpalsya1yearfollowupdatareport AT kodurichaitanya reallifebenefitsofintrajejunallevodopainfusiontherapyinfourpatientswiththeparkinsonianvariantofprogressivesupranuclearpalsya1yearfollowupdatareport AT deepaksai reallifebenefitsofintrajejunallevodopainfusiontherapyinfourpatientswiththeparkinsonianvariantofprogressivesupranuclearpalsya1yearfollowupdatareport AT kalpalarakesh reallifebenefitsofintrajejunallevodopainfusiontherapyinfourpatientswiththeparkinsonianvariantofprogressivesupranuclearpalsya1yearfollowupdatareport AT reddynageswar reallifebenefitsofintrajejunallevodopainfusiontherapyinfourpatientswiththeparkinsonianvariantofprogressivesupranuclearpalsya1yearfollowupdatareport AT chungfayeguy reallifebenefitsofintrajejunallevodopainfusiontherapyinfourpatientswiththeparkinsonianvariantofprogressivesupranuclearpalsya1yearfollowupdatareport AT borgohainrupam reallifebenefitsofintrajejunallevodopainfusiontherapyinfourpatientswiththeparkinsonianvariantofprogressivesupranuclearpalsya1yearfollowupdatareport |